A Need for Refined Senescence Biomarkers and Measures of Senolytics in the Brain

Miranda E. Orr
DOI: https://doi.org/10.3233/jad-231462
2024-03-06
Journal of Alzheimer s Disease
Abstract:Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. Treatments that remove senescent cells, senolytics, improve brain outcomes in AD mice with amyloid-β or tau deposition. 3xTgAD mice develop both AD neuropathologies; however, Ng et al. report low p16INK4a-associated senescence in the brain. Senolytic treatment by genetic removal; dasatinib with quercetin (D+Q), which enter the brain; and ABT-263 with limited brain penetrance all reduced AD neuropathology. Refined measures of senescence and brain exposure would help clarify the benefits of senolytics despite low p16INK4a-associated senescence and potential limited brain penetrance.
neurosciences
What problem does this paper attempt to address?